Evidence map›Paper›PMID 40100513›Full record

ArticleBrain tumor pathology2025

Discordant lymphoma characterized by the coexistence of diffuse large B-cell lymphoma in the brain and mantle cell lymphoma in the colon, rectum, and bone marrow.

Kyosuke Yamaguchi, Go Yamamoto, Otoya Watanabe, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto and 7 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Brain tumor pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kyosuke YamaguchiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan. k.yamaguchi@toranomon.gr.jp.ORCID http://orcid.org/0000-0002-8238-8672
Go YamamotoDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Otoya WatanabeDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Kosei KageyamaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Daisuke KajiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Yuki TayaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Aya NishidaDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Kazuya IshiwataDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Shinsuke TakagiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Hisashi YamamotoDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Yuki Asano-MoriDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Hironori UrugaDepartment of Pathology, Toranomon Hospital, Tokyo, Japan.
Shinji ItoDepartment of Pathology, Toranomon Hospital, Tokyo, Japan.
Yutaka TakazawaDepartment of Pathology, Toranomon Hospital, Tokyo, Japan.
Atsushi WakeDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Shuichi TaniguchiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a rare case of discordant lymphoma characterized by the coexistence of diffuse large B-cell lymphoma (DLBCL) in the brain and mantle cell lymphoma (MCL) in the colon, rectum, and bone marrow. A 63-year-old male patient with consciousness impairment and gait disturbance was admitted to our institution. Head computed tomography scan and contrast-enhanced magnetic resonance imaging showed a mass in the right temporal lobe and rectal wall thickening. Brain biopsy revealed DLBCL, and bone marrow and rectum biopsy showed MCL. According to a polymerase chain reaction analysis of immunoglobulin heavy-chain gene rearrangements using brain and bone marrow specimens, the two lesions were clonally unrelated lymphomas. After five cycles of R-MPV (rituximab, methotrexate, procarbazine, vincristine) therapy and three cycles of R-ESHAP (rituximab, etoposide, cytarabine, cisplatin, methylprednisolone) therapy, the patient received autologous hematopoietic stem cell transplantation using R-MEAM (rituximab, ranimustine, etoposide, cytarabine, melphalan) regimen after bridging therapy with ibrutinib. In addition, he received whole-brain irradiation at a dose of 40 Gy in 20 fractions as consolidation therapy. He did not relapse within 3 years of transplantation. To the best of our knowledge, this is the first case report of DLBCL and MCL coexistence.

Indexed as

Bone Marrow NeoplasmsBrain NeoplasmsColonic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBone MarrowHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedRituximabVincristineRituximabVincristineCentral nervous system lymphomaDiffuse large B-cell lymphoma (DLBCL)Discordant lymphomaHematopoietic stem cell transplantation (HSCT)Mantle cell lymphoma (MCL)

Identifiers

PMID40100513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.